Johnson & Johnson (JNJ)
146.82
-1.71
(-1.15%)
USD |
NYSE |
Apr 25, 16:00
146.96
+0.14
(+0.10%)
Pre-Market: 07:55
Johnson & Johnson Enterprise Value: 360.21B for April 25, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
April 25, 2024 | 360.21B |
April 24, 2024 | 364.33B |
April 23, 2024 | 366.81B |
April 22, 2024 | 365.75B |
April 19, 2024 | 362.84B |
April 18, 2024 | 357.61B |
April 17, 2024 | 355.27B |
April 16, 2024 | 354.50B |
April 15, 2024 | 362.06B |
April 12, 2024 | 361.90B |
April 11, 2024 | 364.96B |
April 10, 2024 | 368.35B |
April 09, 2024 | 373.39B |
April 08, 2024 | 371.70B |
April 05, 2024 | 373.63B |
April 04, 2024 | 373.90B |
April 03, 2024 | 378.14B |
April 02, 2024 | 386.50B |
April 01, 2024 | 386.62B |
March 31, 2024 | 387.61B |
March 28, 2024 | 387.61B |
March 27, 2024 | 387.05B |
March 26, 2024 | 381.78B |
March 25, 2024 | 380.45B |
March 22, 2024 | 380.48B |
Date | Value |
---|---|
March 21, 2024 | 381.73B |
March 20, 2024 | 381.75B |
March 19, 2024 | 382.84B |
March 18, 2024 | 384.16B |
March 15, 2024 | 387.58B |
March 14, 2024 | 390.07B |
March 13, 2024 | 394.62B |
March 12, 2024 | 398.57B |
March 11, 2024 | 394.93B |
March 08, 2024 | 390.81B |
March 07, 2024 | 389.25B |
March 06, 2024 | 390.38B |
March 05, 2024 | 391.90B |
March 04, 2024 | 391.58B |
March 01, 2024 | 397.08B |
February 29, 2024 | 395.30B |
February 28, 2024 | 395.71B |
February 27, 2024 | 394.33B |
February 26, 2024 | 393.71B |
February 23, 2024 | 396.24B |
February 22, 2024 | 392.89B |
February 21, 2024 | 388.63B |
February 20, 2024 | 386.65B |
February 16, 2024 | 383.50B |
February 15, 2024 | 386.80B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
301.41B
Minimum
Mar 23 2020
492.23B
Maximum
Apr 25 2022
417.49B
Average
421.83B
Median
Enterprise Value Benchmarks
Amgen Inc | 198.03B |
Gilead Sciences Inc | 98.95B |
Eli Lilly and Co | 711.57B |
Merck & Co Inc | 359.08B |
Shockwave Medical Inc | 12.04B |
Enterprise Value Related Metrics
Net Income (Quarterly) | 5.354B |
Revenue (Quarterly) | 21.38B |
Total Expenses (Quarterly) | 15.31B |
EPS Diluted (Quarterly) | 2.20 |
Gross Profit Margin (Quarterly) | 69.55% |
Profit Margin (Quarterly) | 25.04% |
Earnings Yield | 9.77% |
Operating Earnings Yield | 6.27% |
Normalized Earnings Yield | 5.575 |